title: Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
abstract: Aripiprazole is an atypical antipsychotic that has been shown to be more effective than placebo and at least as effective as haloperidol and risperidone in the treatment of schizophrenia and schizoaffective disorder. Despite having a well defined licensed dose range, the optimum dose for aripiprazole is yet to be established. Aripiprazole exhibits high affinity for dopamine D(2) receptors, with near maximal receptor occupancy at a dose of 30 mg. Even doses as low as 2 mg, thought not to be clinically effective, have produced striatal D(2) receptor occupancies exceeding 70%, higher than the accepted threshold for antipsychotic effect. In this review we examined the efficacy data from short-term studies of aripiprazole in relapsed schizophrenia or schizoaffective disorder, in order to establish a dose-response relationship for aripiprazole. Results of five fixed-dose studies suggest that the threshold for clinical effect is between 5 and 10 mg/day. In addition, the highest response rate is seen at 10 mg/day. Doses above 20 mg/day do not appear to provide any additional benefit and may be associated with a smaller change in symptom scores. In summary, the data available so far indicate that the optimum dose for aripiprazole is 10 mg/day and that doses above 20 mg/day provide no additional benefit.
authors.affiliation: Pharmacy Department, South London and Maudsley NHS Foundation Trust, Maudsley Hospital, London, SE5 8AZ, UK. shubhra.mace@slam.nhs.uk
authors.forename: Shubhra
authors.initials: S
authors.lastname: Mace
authors.forename: David
authors.initials: D
authors.lastname: Taylor
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068180:Aripiprazole; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy / Q000503:physiopathology; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole
references.citation: Psychiatr Serv. 2007 Jan;58(1):11
references.pmid: 17215406
references.citation: J Psychiatr Res. 2007 Dec;41(11):895-905
references.pmid: 17631314
references.citation: Neuropsychopharmacology. 2002 Aug;27(2):248-59
references.pmid: 12093598
references.citation: J Clin Psychopharmacol. 2008 Aug;28(4):392-400
references.pmid: 18626265
references.citation: J Clin Psychiatry. 2007 Jan;68(1):29-36
references.pmid: 17284127
references.citation: Am J Psychiatry. 2008 Mar;165(3):398; author reply 398-9
references.pmid: 18316435
references.citation: CNS Drugs. 2008;22(1):49-68; discussion 69-72
references.pmid: 18072814
references.citation: J Clin Psychiatry. 2006 Apr;67(4):626-37
references.pmid: 16669728
references.citation: J Psychopharmacol. 1993 Jan;7(4):392-3
references.pmid: 22291004
references.citation: J Clin Psychopharmacol. 2004 Apr;24(2):192-208
references.pmid: 15206667
references.citation: J Psychopharmacol. 2006 Jul;20(4):536-46
references.pmid: 16401666
references.citation: J Clin Psychopharmacol. 2005 Oct;25(5):463-7
references.pmid: 16160622
references.citation: CNS Spectr. 2006 Sep;11(9):691-702; quiz 719
references.pmid: 16946694
references.citation: Arch Gen Psychiatry. 1988 Jan;45(1):71-6
references.pmid: 2892477
references.citation: Nat Med. 2007 Sep;13(9):1102-7
references.pmid: 17767166
references.citation: J Clin Psychiatry. 2002 Sep;63(9):763-71
references.pmid: 12363115
references.citation: J Clin Psychiatry. 2003 Sep;64(9):1048-56
references.pmid: 14628980
references.citation: Psychol Med. 1994 May;24(2):307-16
references.pmid: 7916157
references.citation: J Clin Psychiatry. 2007 Oct;68(10):1480-91
references.pmid: 17960961
references.citation: Am J Psychiatry. 2003 Sep;160(9):1651-8
references.pmid: 12944341
references.citation: J Psychopharmacol. 2006 Jan;20(1):86-90
references.pmid: 16174679
references.citation: Synapse. 2008 Nov;62(11):804-18
references.pmid: 18720421
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Am J Psychiatry. 2008 Aug;165(8):988-95
references.pmid: 18381901
references.citation: Int Clin Psychopharmacol. 2007 Nov;22(6):363-70
references.pmid: 17917555
references.citation: Arch Gen Psychiatry. 2003 Jul;60(7):681-90
references.pmid: 12860772
references.citation: Am J Psychiatry. 2007 Sep;164(9):1411-7
references.pmid: 17728427
references.citation: Am J Psychiatry. 2000 Apr;157(4):514-20
references.pmid: 10739409
references.citation: Eur J Pharmacol. 2008 Jan 14;578(2-3):222-7
references.pmid: 18021764
references.citation: Neuropsychopharmacology. 2008 Dec;33(13):3111-25
references.pmid: 18418366
references.citation: Br J Psychiatry. 2005 Sep;187:235-42
references.pmid: 16135860
references.citation: J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
references.pmid: 12065741